Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Biomarker Guided Treatment in Gynaecological Cancer (Momatec2)

24. mars 2017 oppdatert av: Haukeland University Hospital

MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series.

Part 1: Performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers.

Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. In this study stathmin will be used as integrated biomarker.

Studieoversikt

Studietype

Intervensjonell

Registrering (Forventet)

1300

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Nijmegen, Nederland
        • Har ikke rekruttert ennå
        • Radboud University Hospital
        • Ta kontakt med:
          • Hanny MA Pijnenborg, MD, PhD
        • Ta kontakt med:
          • Casper Reijne, MD
      • Alesund, Norge, 6017
        • Rekruttering
        • Ålesund Hospital
        • Ta kontakt med:
          • Margaret S Lode, MD
      • Førde, Norge, 6812
        • Rekruttering
        • Førde Central Hospital
        • Ta kontakt med:
          • Jostein Tjugum, MD
        • Ta kontakt med:
          • marthe LT Larsson, MD
      • Kristiansand, Norge, 4604
        • Har ikke rekruttert ennå
        • Sørlandet hospital
        • Ta kontakt med:
          • Ane C Munk, MD, PhD
        • Ta kontakt med:
          • ingvild Vistad, MD, PhD
      • Oslo, Norge
        • Rekruttering
        • Akershus University Hospital
        • Ta kontakt med:
          • marie E Engh, MD
      • Stavanger, Norge, 4011
        • Rekruttering
        • Stavanger University Hospital
        • Ta kontakt med:
          • Elisabeth B Nilsen, MD
      • Trondheim, Norge, 7006
        • Rekruttering
        • St Olav University Hospital
        • Ta kontakt med:
          • Nina Nordskar, MD
        • Ta kontakt med:
          • Solveig Tingulstad, MD
    • Hordaland
      • Bergen, Hordaland, Norge, 5053
        • Rekruttering
        • Women's hospital, Haukeland university hospital
        • Ta kontakt med:
        • Ta kontakt med:
      • Lublin, Polen, 20-081
        • Rekruttering
        • Spsk No 1
        • Ta kontakt med:
          • Bartolomiej Barczynski, MD, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 95 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria part 1:

All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.

Exclusion Criteria part 1:

  1. Patients who do not have endometrial cancer
  2. Patients who will or cannot give informed consent (including language barriers)
  3. Patients <18 years of age
  4. Patients who will not get surgical treatment for their endometrial cancer

Inclusion criteria part 2:

  1. Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with advanced disease.
  2. Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.

Exclusion criteria part 2:

  1. Patients not suffering from endometrial or epithelial ovarian cancer
  2. Patients <18 years of age
  3. Patients who do not agree to the proposed treatment or will receive (part of) the treatment in a non-participating centre
  4. Patients who cannot or do not want to give informed consent (including language barriers)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: phase 4 implementation study
The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm. These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding. Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.

Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with <50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).

Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with <50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.

Patients with endometrioid tumours grade 1 or 2, or grade 3 <50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.

Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up.

Eksperimentell: phase 2b biomarker study
For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.

A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.

During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
number of recurrences after primary treatment
Tidsramme: 5 year after diagnosis
The percentage of lymphadenectomy can be reduced safely and significantly, from 70% (MoMaTEC1 study results) to 30% in the MoMaTEC2 study through a better risk stratification of patients, especially better identification of low risk patients. Additionally The percentage of patients who need to be subjected to adjuvant (chemo) therapy can be reduced similarly from 20 to 10%, based on the same, optimised risk stratification and better identification of low risk patients. Patients will be rigorously followed during 5 years to detect any unexpected increase in the percentage of patients suffering a recurrence compared to the historical MoMaTEC1 cohort.
5 year after diagnosis
stathmin levels
Tidsramme: duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
stathmin level will be measured in metastatic tissue and related to response to treatment using Response Evaluation Criteria In Solid Tumors (RECIST) criteria
duration of complete or partial treatment response in metastatic setting (expected duration less than one year)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Quality of life measurements
Tidsramme: 5 years post treatment
Quality of life will be measured through validated questionnaires (EORTC QLQ-C30 and EORTC QLQ-EN24).
5 years post treatment
correlation of stathmin llevels in tumor, urine and blood
Tidsramme: duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
stathmin tumor levels, urine levels and blood levels will be correlated.
duration of complete or partial treatment response in metastatic setting (expected duration less than one year)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Henrica MJ Werner, MD PhD MRCOG, Haukeland University Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. oktober 2015

Primær fullføring (Forventet)

1. desember 2020

Studiet fullført (Forventet)

1. desember 2033

Datoer for studieregistrering

Først innsendt

7. juli 2015

Først innsendt som oppfylte QC-kriteriene

4. september 2015

Først lagt ut (Anslag)

7. september 2015

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. mars 2017

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. mars 2017

Sist bekreftet

1. mars 2017

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere